• More Than $850M Raised for Inflammatory Breast Cancer Research
  • Fertility Clinics and Breast Cancer ‘Previvor’ Team Up to Raise Awareness About Genetic Risk of Disease
  • Blood Test May Identify Breast Cancer Years Before Symptoms Appear, Pilot Study Suggests
  • Most Breast Cancers Found by Hand, MammaCare Researchers Say
  • First Patient Dosed in Phase 3 Trial of Tucatinib-Kadcyla Combo for Advanced HER2-Positive Breast Cancer
  • Hormone Therapy Has More Long-term Impact on Quality of Life Than Chemo, Study Suggests
  • Pathologist Creates Program Allowing Patients to Face Their Cancer Head-on
  • Seattle Genetics’ Tucatinib Extends Survival Outcomes in Metastatic HER2-positive Breast Cancer Patients, Phase 2 Trial Shows
  • FDA Supports Use of Anti-diarrheal Medications with Nerlynx
  • Bempegaldesleukin-Opdivo Combo Leads to Prolonged Responses in TNBC Patients, Phase 1/2 Trial Shows
  • Daiichi Sankyo Files New Drug Application for DS-8201 in Japan
  • Trastuzumab Deruxtecan Gets FDA Priority Review for Metastatic HER2-Positive Breast Cancer